Funding for this research was provided by:
Received: 20 March 2019
Accepted: 12 June 2019
First Online: 21 June 2019
Ethics approval and consent to participate
: The study was conducted according to the principles expressed in the Declaration of Helsinki. The COPUS trial (parent study) including qualitative inquiry was approved by the Danish Data Protection Agency (file no.: 2012-58-0004) and the National Committee on Health Research Ethics (H-17018798). Written informed consent was provided by all participants. Parental consent was not required because all participants enrolled in the study were over the age of 18 (i.e. age of majority according to Danish law). All personal identifiers have been removed or disguised so that the persons described here are not identifiable and cannot be identified through the details of the article.
: Not applicable.
: BHE has received lecture fees and is part of Advisory Boards of Bristol-Myers Squibb, Eli Lilly and Company, Janssen-Cilag, Otsuka Pharma Scandinavia AB, Takeda Pharmaceutical Company and Lundbeck Pharma A/S. Remaining authors declare that they have no competing interests.